Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Nusinersen Treatment for Spinal Muscular Atrophy: Retrospective Multicenter Study of Pediatric and Adult Patients in Kuwait

Asma Tawari
* ,
Mohammad Zakaria
,
Walaa Kamel
ORCID logo ,
Laila Bastaki
,
Gamal Ahmed Ismail Elghazawi
,
Mohamed Esmat Anwar Ali
,
Dalia Salota
,
Amer Attia
,
Ehab Elsayed Ali Elanay
,
Osama Shalaby
,
Fatema Alqallaf
,
Vesna Mitic
,
Nayera Shaalan
Version 1 : Received: 18 April 2024 / Approved: 19 April 2024 / Online: 19 April 2024 (08:05:23 CEST)

How to cite: Tawari, A.; Zakaria, M.; Kamel, W.; Bastaki, L.; Elghazawi, G.A.I.; Ali, M.E.A.; Salota, D.; Attia, A.; Elanay, E.E.A.; Shalaby, O.; Alqallaf, F.; Mitic, V.; Shaalan, N. Nusinersen Treatment for Spinal Muscular Atrophy: Retrospective Multicenter Study of Pediatric and Adult Patients in Kuwait. Preprints 2024, 2024041315. https://doi.org/10.20944/preprints202404.1315.v1 Tawari, A.; Zakaria, M.; Kamel, W.; Bastaki, L.; Elghazawi, G.A.I.; Ali, M.E.A.; Salota, D.; Attia, A.; Elanay, E.E.A.; Shalaby, O.; Alqallaf, F.; Mitic, V.; Shaalan, N. Nusinersen Treatment for Spinal Muscular Atrophy: Retrospective Multicenter Study of Pediatric and Adult Patients in Kuwait. Preprints 2024, 2024041315. https://doi.org/10.20944/preprints202404.1315.v1

Abstract

Spinal muscular atrophy is a neuromuscular genetic condition associated with progressive muscle weakness and atrophy. Nusinersen is an antisense oligonucleotide therapy approved for the treatment of 5q spinal muscular atrophy in pediatric and adult patients. The objective of this clinical case series is to describe the efficacy and safety of nusinersen in treating spinal muscular atrophy in 20 pediatric and 18 adult patients across six treatment centers in Kuwait. Functional motor assessments (Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders, Hammersmith Functional Motor Scale Expanded, and Revised Upper Limb Module) were used to assess changes in motor function following nusinersen treatment. Safety assessment involved clinical monitoring of adverse events. The results demonstrate clinically meaningful or considerable improvement in motor performance for nearly all patients, lasting over 4 years in some cases. 70% of patients in the pediatric cohort and 72% of patients in the adult cohort achieved clinically meaningful improvement in motor function following nusinersen treatment. Additionally, nusinersen was well-tolerated in both cohorts. These findings add to the growing body of evidence relating to the clinical efficacy and safety of nusinersen.

Keywords

spinal muscular atrophy; neuromuscular disease; nusinersen; antisense oligonucleotide; pediatrics

Subject

Medicine and Pharmacology, Neuroscience and Neurology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.